<DOC>
	<DOCNO>NCT01018238</DOCNO>
	<brief_summary>This trial conduct United States America ( USA ) . The aim clinical trial investigate safety , tolerability , pharmacokinetics sign bioactivity increase repeat dos NNC 151-0000-0000 subject Systemic Lupus Erythematosus ( SLE ) .</brief_summary>
	<brief_title>An Investigation NNC 0151-0000-0000 Subjects With Systemic Lupus Erythematosus ( SLE )</brief_title>
	<detailed_description>The trial terminate patient expose trial drug base new finding indicate dose escalation multiple dos perform different trial population .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Diagnosis systemic lupus erythematosus ( SLE ) Disease duration : 6 month longer Stable , mild moderately active systemic lupus erythematosus ( SLE ) Receiving stable maintenance therapy Significant Lupus Nephritis Active central nervous system ( CNS ) disease Significant arterial venous thrombosis ( blood clot ) within 12 month prior trial start Body weight 260 lbs/120 kg History alcohol substance abuse History cancer Infections Viral infection : HIV , Hepatitis B C , EpsteinBarr Virus ( EBV ) , Cytomegalovirus ( CMV ) , VaricellaZoster Virus ( VZV ) , Herpes Simplex Virus ( HSV1 HSV2 ) Tuberculosis Severe systemic bacterial , viral fungal infection within past 12 month prior trial start Immunosuppressive immune modulate therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>